Background
==========

Peripheral Arterial Disease (PAD) is a common disorder with a prevalence estimated at 16% in those aged over 55 years and 29% in high-risk groups \[[@B1],[@B2]\]. PAD is a sign of widespread atherosclerosis also affecting coronary, cerebral and renal arteries. PAD is associated with a significant reduction in Quality of Life (QoL) and greater risk of acute cardiovascular events \[[@B3],[@B4]\]. The increased risk for cardiovascular morbidity, such as myocardial infarction and stroke, and increased risk for mortality is also observed in asymptomatic patients \[[@B5]\]. The Cardiovascular consequences of PAD, are known to be expensive and contribute substantially to national health care costs \[[@B6]\].

European Society of Cardiology (ESC), American Heart Association (AHA) and American College of Cardiology (ACC) clinical practice guidelines recommend low dose aspirin to reduce the cardiovascular events and mortality in symptomatic PAD patients \[[@B7],[@B8]\]. Clopidogrel is recommended as an effective alternative anti-platelet therapy to aspirin for secondary prevention in PAD \[[@B8]\]. Ankle Brachial Index (ABI) is used for detection of PAD. The ABI is calculated by measuring both arm and leg blood pressure (at ankle level). This reliable and inexpensive test is highly sensitive and specific for PAD. However, ABI screening in asymptomatic patients is a controversial topic among the health professionals. United States preventive services task force (USPSTF) assigned a "D" recommendation to the routine screening of PAD \[[@B9]\]. This recommendation is intensely debated and a routine targeted screening for PAD is recommended to increase the frequency of diagnosis, improve the use of recommended medical therapies, and consequently reduce cardiovascular morbidity and mortality rates \[[@B10]\]. Researchers have voiced that 'it's not just about legs' and ABI measurement in asymptomatic individuals should be regarded as the biomarker of cardiovascular disease risk \[[@B11]\]. While expansion of the evidence base for PAD screening is recommended in the year 2011 focussed update of the guidelines \[[@B12]\], targeted ABI screening is recommended by all professional vascular societies including the ACC \[[@B8]\].

The Rotterdam study has identified risk factors that are most strongly associated with PAD such as older age, cigarette smoking, diabetes mellitus, hypercholesterolemia and hypertension \[[@B13]\]. These risk factors can be used to guide targeted ABI screening in a general population over 55 years of age.

In current health care practice, asymptomatic PAD often remains undiagnosed and opportunities for secondary prevention are missed \[[@B2]\]. Therefore, there is a clinical need of early detection of asymptomatic PAD and for the initiation the appropriate preventive treatment in a high risk population. Although, prevention and subsequent treatment comes at a certain cost the secondary prevention of cardio-vascular consequences in PAD patients may at the same time improve prognosis and save healthcare resources. This study aims to determine the cost-effectiveness of PAD screening using ABI and subsequent preventive treatment in high risk individuals at high risk for acute cardiovascular events with low dose aspirin or clopidogrel compared to no screening and treatment.

Methods
=======

A model-based economic evaluation of targeted ABI screening in high-risk group was performed taking lifetime costs and health effects in account for a Dutch health care setting. Microsoft Excel 2010^©^ software was used for this modelling work.

Future costs and outcomes were discounted at the rates of 4% and 1.5% respectively, as per the Dutch guidelines for pharmaco-economic research \[[@B14]\]. This study was conducted from the societal perspective and indirect costs (productivity loss) were taken into account.

Model approach
--------------

The hypothetical population consists of asymptomatic males and females aged 55 years with at least one of the vascular risk factors identified in the Rotterdam study \[[@B13]\].

The intervention is one time screening in a high risk population at the age of 55 years using ABI, the current standard test to detect PAD in primary care. Screening in principle is intended to take place in the general practitioner's office, in a similar manner as 'The prevention visit' for the cardiovascular risk assessment, defined in the Dutch College of General Practitioners\' practice guideline \[[@B15]\]. We modelled that all ABI test positive patients will receive preventive treatment with low dose aspirin in the base case analysis. In a scenario analysis low dose aspirin is replaced with clopidogrel as preventive treatment in patients with a positive test.

ABI screening is compared to no screening of the high risk population and preventive treatment is only given to the incidentally diagnosed or incidentally symptomatic patients. Model Outcomes were life years (LYs), quality adjusted life years (QALYs) and costs. The model has a time horizon of a life time as the hypothetical patient cohort was followed until death. The model cycle duration was one year.

Model structure
---------------

Based on a systematic review of modelling approaches for PAD, we used a combination of two modelling approaches: a decision tree and a Markov state transition model shown in the Figure [1](#F1){ref-type="fig"} and Figure [2](#F2){ref-type="fig"}\[[@B16]\]. The decision tree was used to determine the number of screened individuals falling into the categories of test positive or test negative on the basis of test accuracy and prevalence of PAD. A Markov model was subsequently used to model the on-going risk of cardiovascular events over a lifetime.

![Decision tree.](1471-2458-14-89-1){#F1}

![Markov model.](1471-2458-14-89-2){#F2}

The model assumes that the patient is always in one of a finite number of states of health referred to as Markov states. The time horizon of the analysis is divided into equal increments of time, referred to as Markov cycles, in this case one year. During each cycle, the cohort of patients is redistributed over the Markov states, thus theoretically a patient may make a transition from one state to another. Each state is assigned a utility and a cost. Total costs and utility for screening versus no-screening are calculated depending upon the distribution of the cohort over the Markov states and the length of time spent in each state \[[@B17]\].

We included all the relevant cardiovascular health states in the Markov model (no PAD, asymptomatic PAD, and symptomatic PAD, post amputation, post myocardial infarction, post stroke, post bleed-in treated patients and the absorbing state of death). Risk reductions of cardiovascular events and mortality as well as increased bleeding risk caused by the preventive anti-platelet treatment were modelled accordingly in our model. All the model parameters are shown in Table [1](#T1){ref-type="table"}.

###### 

Model parameters and distribution used in the probabilistic sensitivity analyses

  **Model parameter**                                         **Value**   **Probability distribution**   **Moments of the probability distribution ά/min, β/max**          **Source**
  ----------------------------------------------------------- ----------- ------------------------------ ----------------------------------------------------------------- ------------
  **Discount rates**                                                                                                                                                        
  Cost discount rate                                          4%          Fixed                          \-                                                                \[[@B14]\]
  Outcome discount rate                                       1.5%        Fixed                          \-                                                                \[[@B14]\]
  **Costs (Euros)\***                                                                                                                                                       
  Cost of ankle brachial index test                           74†         BETA Pert                      55.7;92.8                                                         MUMC‡
  Annual cost of PAD treatment                                2369        GAMMA                          325.09;7.29                                                       \[[@B18]\]
  Annual cost of Aspirin                                      10          Fixed                                                                                            \[[@B19]\]
  Annual cost of Clopidogrel                                  19          Fixed                                                                                            \[[@B19]\]
  Costs of Amputation                                         14343†      BETA Pert                      10683;17804                                                       \[[@B20]\]
  Cost of AMI in first year                                   25328       GAMMA                          100;253.27                                                        \[[@B21]\]
  Annual costs of MI treatment in subsequent years            3584        GAMMA                          99.92;35.86                                                       \[[@B21]\]
  Cost of stroke in first year                                27964       GAMMA                          99.99;279.66                                                      \[[@B21]\]
  Annual costs of treatment of stroke in subsequent years     10646       GAMMA                          99.99;106.47                                                      \[[@B21]\]
  Costs of bleeding                                           3457        GAMMA                          99.87;34.61                                                       \[[@B21]\]
  **ABI test accuracy**                                                                                                                                                     
  Sensitivity                                                 0.90†       BETA Pert                      0.68;1                                                            \[[@B22]\]
  Specificity                                                 0.95†       BETA Pert                      0.71;1                                                            \[[@B22]\]
  **Incidence/prevalence of PAD**                                                                                                                                           
  Prevalence of PAD                                           0.184       BETA                           1372;6082                                                         \[[@B6]\]
  Annual incidence of PAD in 55--64 years aged                0.005       BETA                           See Additional file [1](#S1){ref-type="supplementary-material"}   \[[@B23]\]
  Annual incidence of PAD in 65--74 years aged                0.007       BETA                           See Additional file [1](#S1){ref-type="supplementary-material"}   \[[@B23]\]
  Annual incidence of PAD in 75--84 years aged                0.008       BETA                           See Additional file [1](#S1){ref-type="supplementary-material"}   \[[@B23]\]
  Annual incidence of PAD in \>85 years aged                  0.010       BETA                           See Additional file [1](#S1){ref-type="supplementary-material"}   \[[@B23]\]
  **Event probabilities**                                                                                                                                                   
  Probability of amputation in patients with no PAD           0.003       BETA                           32;11734                                                          \[[@B24]\]
  Probability of AMI in patients with no PAD                  0.008       BETA                           89;11677                                                          \[[@B24]\]
  Probability of stroke in patients with no PAD               0.008       BETA                           94;11672                                                          \[[@B24]\]
  Probability of amputation in PAD patients                   0.016       BETA                           140;8441                                                          \[[@B24]\]
  Probability of AMI in PAD patients                          0.013       BETA                           111;8470                                                          \[[@B24]\]
  Probability of stroke in PAD patients                       0.019       BETA                           165;8416                                                          \[[@B24]\]
  Probability of symptomatic PAD                              0.3         BETA                           138;320                                                           \[[@B25]\]
  Relative risk in PAD patients on low dose aspirin           0.78        BETA                           25.45;7.2                                                         \[[@B26]\]
  Probability of bleeding in PAD patients on aspirin          0.026       BETA                           255;9311                                                          \[[@B27]\]
  Relative risk in PAD patients on Clopidogrel                0.616       BETA                           See Additional file [1](#S1){ref-type="supplementary-material"}   \[[@B28]\]
  Probability of bleeding in PAD patients on Clopidogrel      0.020       BETA                           191;9386                                                          \[[@B27]\]
  **Mortality in 'untreated' patients**                                                                                                                                     
  Annual probability of death in PAD patients                 0.037       BETA                           323;8258                                                          \[[@B24]\]
  Probability of death in post Amputation                     0.155       BETA                           4297;21281                                                        \[[@B29]\]
  annual probability of death in post MI alive patients       0.028       BETA                           521;17492                                                         \[[@B24]\]
  annual probability of death in post stroke alive patients   0.031       BETA                           1212;37390                                                        \[[@B24]\]
  **Utility**                                                                                                                                                               
  PAD                                                         0.652       BETA                           0.8;0.4                                                           \[[@B30]\]
  Amputation                                                  0.45        BETA                           210.8;257.7                                                       \[[@B31]\]
  Post MI                                                     0.671       BETA                           69.3;34                                                           \[[@B30]\]
  Post stroke                                                 0.519       BETA                           2.7;2.5                                                           \[[@B30]\]
  Post bleed                                                  0.627       BETA                           405.6;241.13                                                      \[[@B30]\]

\*All costs were converted to 2012 Dutch costs using harmonized index of consumer prices (HICP).

‡This cost was obtained from the Financial department of Maastricht University Medical Centre.

†Mode for BETA Pert distribution.

Transition probabilities
------------------------

Transition probabilities for PAD patients were calculated from the REACH (Reduction of Athero-thrombosis for Continued Health) registry. This multinational database contains 68,375 consecutive outpatients from 5587 physician practices in 44 countries and was enrolled between December 2003 and June 2004 \[[@B24]\]. Patients on anti-platelet preventive treatment have reduced cardiovascular morbidity and mortality but on the other hand this treatment increases the risk of bleeding in the recipients. Transition probabilities for cardiovascular events in patients receiving Aspirin were calculated from a meta-analysis of randomised trials 'Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease' \[[@B26]\]. Probabilities for Clopidogrel were calculated from a Cochrane review of anti-platelet agents for intermittent claudication \[[@B28]\]. Bleeding risks in patients receiving low dose aspirin or clopidogrel were assigned from a randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) \[[@B27]\].

Costs
-----

The acute phase costs and subsequent costs of cardiovascular events were taken from Thurston et al. \[[@B21]\] and the costs of amputation and of cardiovascular death are from Oostenbrink et al. \[[@B20]\]. The annual costs for an average PAD patient were published by van Asselt et al. \[[@B18]\] Dutch costs of anti-platelet medications aspirin and clopidogrel were obtained from the medicine cost website in the Netherlands \[[@B19]\]. Travel costs for attending the PAD screening were calculated based on the average distance to a primary practice. The average distance to a Dutch primary practice is 1.1 KM \[[@B32]\]. Cost of a session at a primary care physician and productivity loss for a 55 years old individual in the Netherlands are published in the Dutch manual for costing in economic evaluations \[[@B33]\]. All costs used in the model were converted to Year 2012 Dutch costs using harmonized index of consumer prices data from the Dutch bureau of statistics \[[@B34]\].

Utilities
---------

Since Dutch utility scores for the health states defined in our model were not found in the literature, we used Sullivan et al. to estimate utilities for all the health states except amputation \[[@B30]\]. The utility of an amputee using standard gamble method was taken from Berry et al. \[[@B31]\].

Analysis
--------

Discounted and undiscounted expected life years and QALYs (1.5% discount rate), and costs (discount rate 4%) for each strategy were calculated. Based on the discounted expected values, the Incremental Cost Effectiveness Ratios (ICERs) of the screening and treatment strategy were calculated over the standard existing practice of no screening and preventive treatment with low dose aspirin for incidentally diagnosed or symptomatic patients only.

The results of cost-effectiveness analysis were based on Probabilistic Sensitivity Analysis (PSA). Results of 1000 Monte Carlo simulations were graphically displayed in the form of cost-effectiveness planes (CE planes) and the subsequent probability of being cost-effective at different values of willingness to pay (WTP) thresholds was shown as cost-effectiveness acceptability curves (CEACs).

One way sensitivity analyses were performed to identify the two most influential model parameters affecting model outputs. For this purpose, upper and lower limits of 95% confidence interval of model parameters were used. Then, a two way sensitivity analysis was conducted for combinations of values tested for these two most influential parameters.

Scenario analysis
-----------------

We performed a scenario analysis by replacing routinely prescribed low dose aspirin with a relatively new anti-platelet drug clopidogrel for the secondary prevention of cardiovascular events in identified PAD patients.

Results
=======

Cost-effectiveness analysis
---------------------------

The expected model outcomes show that the targeted ABI screening and treatment with low dose aspirin produce 21.79 mean LYs and 15.66 mean QALYs for a cost of 26,548 Euros. The cost of PAD screening and treatment followed by low dose aspirin was 1503 Euros lower compared to 'no screening' and 0.07 QALYs were gained (Table [2](#T2){ref-type="table"}). Therefore, ABI screening followed by preventive treatment with low dose aspirin is a dominant strategy. The relationship between costs and effects and the uncertainty surrounding these estimates are shown in the cost effectiveness planes in the Figure [3](#F3){ref-type="fig"}. Monte Carlo simulation shows that the 88% of ICER dots are in the right lower quadrant indicating that the strategy 'PAD screening' tended to have favourable health outcomes against lower costs in comparison with a strategy of 'no screening'. The probability of being cost effective at different values of willingness to pay (WTP) thresholds was shown as cost effectiveness acceptability curves (CEACs) in the Figure [4](#F4){ref-type="fig"}. The curves show the probability of PAD screening being cost effective at a range of Willingness To Pay thresholds. There is 88% probability of PAD screening being cost effective at the WTP of 40000 Euros.

###### 

Results -- base case analysis and scenario analysis

  **PROBABILISTIC RESULTS (discounted)**                                                                                              
  ------------------------------------------ ------------------ ----------- --------- ----------- ------------ --------- ------------ -----------
  **Diagnostic test**                          **Treatment**     **Costs**   **LYs**   **QALYs**   **iCosts**   **iLY**   **iQALYs**   **iCERs**
  **Base case**                                                                                                                             
  No screen                                   Low dose aspirin     28052      20.69      15.58                                              
  ABI screening                               Low dose aspirin     26548      21.79      15.66       -1503       1.10       0.007      Dominant
  **Scenario analysis with Clopidogrel**                                                                                              
  No screen                                     Clopidogrel        29464      22.33      15.95                                              
  ABI                                           Clopidogrel        27681      22.57      16.17       -1783       0.24        0.22      Dominant
  **PROBABILISTIC RESULTS (undiscounted)**                                                                                            
  **Diagnostic test**                          **Treatment**     **Costs**   **LYs**   **QALYs**   **iCosts**   **iLY**   **iQALYs**        
  **Base case**                                                                                                                       
  No screen                                   Low dose aspirin     63155      26.32      19.40                                              
  ABI screening                               Low dose aspirin     59544      27.47      19.50       -3611       1.15        0.11           
  **Scenario analysis with Clopidogrel**                                                                                              
  No screen                                     Clopidogrel        67799      28.30      19.96                                              
  ABI                                           Clopidogrel        63759      28.66      20.27       -4039       0.36        0.31           

![**incremental Cost-effectiveness planes.** Shows that PAD screening followed by low dose aspirin treatment was a dominant strategy (less costly, more effective) in 88% of simulations.](1471-2458-14-89-3){#F3}

![**Cost-effectiveness acceptability curves.** The acceptability curves show that ABI Screening followed by treatment with low dose aspirin remains 100% cost-effective at willingness to pay (WTP) thresholds of zero to 11000 Euros and 88% cost-effective at a WTP threshold of 40000 Euros.](1471-2458-14-89-4){#F4}

Scenario analysis with the use of clopidogrel as an alternative anti-platelet therapy produced similar results indicating dominance over 'no screening' (Table [2](#T2){ref-type="table"}).

The one way sensitivity analysis identified PAD prevalence and relative risk reduction by low dose aspirin in the treated PAD patients, as the two most influential model parameters. Although the ICER for ABI screening remained dominant for all the variations in parameter values, two way sensitivity analysis varying PAD prevalence and relative risk reduction by aspirin showed a consistent QALY gain by either increasing the prevalence of PAD or relative risk reduction by low dose aspirin.

Discussion
==========

Our cost-effectiveness model output suggests that targeted screening of high risk individuals and consequent secondary prevention of cardiovascular events by anti-platelet medication is cost effective and results in significant health gain by reducing cardiovascular events in PAD patients.

The analysis has been performed from societal perspective and all direct and indirect costs are incorporated for all the health states in the model. Our analysis interprets that PAD screening and anti-platelet preventive treatment is a highly cost-effective intervention. Changing the analysis perspective to health care payer's, would further strengthen this interpretation. This is the case in countries like the United Kingdom where health care is financed by general taxation, a health care provider's (National Health Services) perspective is used in pharmaco-economic analyses and only direct costs are covered.

A recent meta-analysis concluded that measurement of the ankle brachial index may improve the accuracy of cardiovascular risk prediction beyond the Framingham Risk Score \[[@B35]\]. After adjustment for the Framingham risk score, the ABI provided significant improvement in predicting cardiovascular risk independent of established risk factors in a broad population. There is unequivocal evidence establishing the importance of targeted ABI screening \[[@B36],[@B37]\].

In our model costs and effects were modeled for aspirin and clopidogrel. The CAPRIE trial data show that clopidogrel is more effective than aspirin in reducing cardiovascular events in the subgroup of patients with PAD \[[@B27]\]. However, with branded clopidogrel (Plavix), cost was a major barrier for longer-term use. Plavix (clopidogrel) lost its patent protection from May 2012 and the generic form of clopidogrel is available at a much lower cost. Since branded Plavix may have been cost-prohibitive in certain non-reimbursement settings, there will likely be an increase in compliance with long-term generic clopidogrel therapy. Economic model results for the use of clopidogrel in PAD patients were in line with previous studies establishing the cost-effectiveness of this drug \[[@B38],[@B39]\]. These results were expected as generic clopidogrel costs only few Euros more than aspirin and provides higher risk reduction from C The limitation of our model is that the costs and health outcomes of only antiplatelet treatment are modeled. Depending upon the identified risk factors in the individual patients many additional medication interventions such as statins and tension lowering medications are prescribed for the medical management of PAD. However, our study focusses on antiplatelet treatment using Aspirin or Clopidogrel as this is the most commonly prescribed medication in almost all the patients. In order to model the additional therapies for each subgroup of high risk patients a much more complex model is needed.

ABI has been in wide use at specialized vascular clinics but its application in primary practice is limited. With a high degree of diagnostic accuracy and as much prognostic information, ABI screening is a cost-effective but underused primary care tool to detect PAD. Mohler et al. found that the time to perform ABI, staff constrains and lack of reimbursement are the most important barriers in its use and appropriate measures are required to deal with these barriers \[[@B40]\]. However, this cost-effective analysis clearly indicates that the ABI screening is a highly cost-effective clinical tool to be applied in the primary care.

In the real world scenario, compliance to the ABI screening and to the preventive treatment thereafter, in an apparently healthy population could pose a challenge. However, factors like the noninvasive nature of the ABI testing and routine primary care visits of high risk individuals are likely to contribute to good compliance. Although lower compliance to the screening programme may affect the overall cost effectiveness results, it is unlikely to negate the cost-effectiveness of ABI screening altogether because of the high probability of the screening programme to be cost-effective as shown in the cost-effectiveness plane (Figure [4](#F4){ref-type="fig"}).

Our results are in line with a previously published modeling study by Sigvant et al. to assess the cost-effectiveness of various therapeutic agents in asymptomatic PAD patients. Aspirin as one of the preventive therapies produced similar health outcomes in 55 year-old patients as our model \[[@B41]\].

In line with ACC/AHA guidelines, this modeling study is only based upon risk reduction by preventive anti-platelet therapy given to the PAD patients. Additional cardiovascular risk reducing treatments such as exercise therapy, lipid lowering statins and blood pressure lowering drugs are also prescribed in PAD. Further research is required to quantify the consolidated effects of diverse preventive options in a heterogenic PAD population.

Conclusions
===========

This study has assessed the impact of PAD screening using long term clinical and economic outcomes. The results show that targeted ABI screening and consequent secondary prevention of cardiovascular events using low dose aspirin or clopidogrel is a cost-effective strategy. Our study results provide one of the building blocks of evidence expansion for advocating PAD screening and the promotion of its more widespread use to detect and treat PAD patients. Implementation of targeted PAD screening and subsequent treatment in primary care practices and in public health programs is likely to improve the societal health and to save health care costs by reducing catastrophic cardiovascular events.
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